Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use

Tangeria R. Adams, Julia H. Arnsten, Yuming Ning, Shadi Nahvi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Few studies have evaluated treatment for co-occurring cannabis and tobacco use. The objective of this pilot study was to evaluate the feasibility and preliminary effectiveness of varenicline for co-occurring cannabis and tobacco use. Participants who reported cannabis use on ≥5 days per week were recruited from an urban, outpatient opioid treatment program (OTP). Participants were randomized to either four weeks of standard OTP clinical care (SCC; medication-assisted treatment for opioid use disorder and individual behavioral counseling), followed by four weeks of SCC plus varenicline (SCC+VT), or to four weeks of SCC+VT followed by four weeks of SCC. All participants contributed feasibility and outcome data during both study phases. Of 193 persons screened, seven were enrolled. Retention at eight weeks was 100%. No adverse effects prompted varenicline discontinuation. Participants reported lower cannabis craving during the SCC+VT phase compared to baseline, and lower frequencies and quantities of cannabis use compared to both baseline and the SCC alone phase. In the SCC+VT phase, participants also reported fewer cigarettes per day. Among persons with co-occurring cannabis and tobacco use, varenicline is well-tolerated and may reduce cannabis craving, cannabis use, and tobacco use.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Psychoactive Drugs
DOIs
StateAccepted/In press - Sep 29 2017

Fingerprint

Tobacco Use
Cannabis
Opioid Analgesics
Varenicline
Therapeutics
Tobacco Products
Counseling
Outpatients

Keywords

  • Cannabis
  • concurrent use
  • feasibility
  • tobacco
  • varenicline

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychology(all)

Cite this

Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use. / Adams, Tangeria R.; Arnsten, Julia H.; Ning, Yuming; Nahvi, Shadi.

In: Journal of Psychoactive Drugs, 29.09.2017, p. 1-7.

Research output: Contribution to journalArticle

@article{56e68228743e4424a83ae76a31e08e73,
title = "Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use",
abstract = "Few studies have evaluated treatment for co-occurring cannabis and tobacco use. The objective of this pilot study was to evaluate the feasibility and preliminary effectiveness of varenicline for co-occurring cannabis and tobacco use. Participants who reported cannabis use on ≥5 days per week were recruited from an urban, outpatient opioid treatment program (OTP). Participants were randomized to either four weeks of standard OTP clinical care (SCC; medication-assisted treatment for opioid use disorder and individual behavioral counseling), followed by four weeks of SCC plus varenicline (SCC+VT), or to four weeks of SCC+VT followed by four weeks of SCC. All participants contributed feasibility and outcome data during both study phases. Of 193 persons screened, seven were enrolled. Retention at eight weeks was 100{\%}. No adverse effects prompted varenicline discontinuation. Participants reported lower cannabis craving during the SCC+VT phase compared to baseline, and lower frequencies and quantities of cannabis use compared to both baseline and the SCC alone phase. In the SCC+VT phase, participants also reported fewer cigarettes per day. Among persons with co-occurring cannabis and tobacco use, varenicline is well-tolerated and may reduce cannabis craving, cannabis use, and tobacco use.",
keywords = "Cannabis, concurrent use, feasibility, tobacco, varenicline",
author = "Adams, {Tangeria R.} and Arnsten, {Julia H.} and Yuming Ning and Shadi Nahvi",
year = "2017",
month = "9",
day = "29",
doi = "10.1080/02791072.2017.1370746",
language = "English (US)",
pages = "1--7",
journal = "Journal of Psychoactive Drugs",
issn = "0279-1072",
publisher = "Haight-Ashbury Publications",

}

TY - JOUR

T1 - Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use

AU - Adams, Tangeria R.

AU - Arnsten, Julia H.

AU - Ning, Yuming

AU - Nahvi, Shadi

PY - 2017/9/29

Y1 - 2017/9/29

N2 - Few studies have evaluated treatment for co-occurring cannabis and tobacco use. The objective of this pilot study was to evaluate the feasibility and preliminary effectiveness of varenicline for co-occurring cannabis and tobacco use. Participants who reported cannabis use on ≥5 days per week were recruited from an urban, outpatient opioid treatment program (OTP). Participants were randomized to either four weeks of standard OTP clinical care (SCC; medication-assisted treatment for opioid use disorder and individual behavioral counseling), followed by four weeks of SCC plus varenicline (SCC+VT), or to four weeks of SCC+VT followed by four weeks of SCC. All participants contributed feasibility and outcome data during both study phases. Of 193 persons screened, seven were enrolled. Retention at eight weeks was 100%. No adverse effects prompted varenicline discontinuation. Participants reported lower cannabis craving during the SCC+VT phase compared to baseline, and lower frequencies and quantities of cannabis use compared to both baseline and the SCC alone phase. In the SCC+VT phase, participants also reported fewer cigarettes per day. Among persons with co-occurring cannabis and tobacco use, varenicline is well-tolerated and may reduce cannabis craving, cannabis use, and tobacco use.

AB - Few studies have evaluated treatment for co-occurring cannabis and tobacco use. The objective of this pilot study was to evaluate the feasibility and preliminary effectiveness of varenicline for co-occurring cannabis and tobacco use. Participants who reported cannabis use on ≥5 days per week were recruited from an urban, outpatient opioid treatment program (OTP). Participants were randomized to either four weeks of standard OTP clinical care (SCC; medication-assisted treatment for opioid use disorder and individual behavioral counseling), followed by four weeks of SCC plus varenicline (SCC+VT), or to four weeks of SCC+VT followed by four weeks of SCC. All participants contributed feasibility and outcome data during both study phases. Of 193 persons screened, seven were enrolled. Retention at eight weeks was 100%. No adverse effects prompted varenicline discontinuation. Participants reported lower cannabis craving during the SCC+VT phase compared to baseline, and lower frequencies and quantities of cannabis use compared to both baseline and the SCC alone phase. In the SCC+VT phase, participants also reported fewer cigarettes per day. Among persons with co-occurring cannabis and tobacco use, varenicline is well-tolerated and may reduce cannabis craving, cannabis use, and tobacco use.

KW - Cannabis

KW - concurrent use

KW - feasibility

KW - tobacco

KW - varenicline

UR - http://www.scopus.com/inward/record.url?scp=85030175174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030175174&partnerID=8YFLogxK

U2 - 10.1080/02791072.2017.1370746

DO - 10.1080/02791072.2017.1370746

M3 - Article

C2 - 28952897

AN - SCOPUS:85030175174

SP - 1

EP - 7

JO - Journal of Psychoactive Drugs

JF - Journal of Psychoactive Drugs

SN - 0279-1072

ER -